Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

Pugliese, Daniela; Guidi, Luisa; Privitera, Giuseppe; Armuzzi, Alessandro

doi:10.1080/03007995.2019.1673581

Cited by 5 publications

(1 citation statement)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One patient in our cohort (patient 5) experienced a reactivation of pouchitis after secukinumab induction and a partial improvement was observed after the introduction of vedolizumab. As previously reported, IL17 inhibition can be associated with new onset and relapse of IBD 11 : in such cases, gut-selective Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/doi/10.1093/ecco-jcc/jjaa149/5872608 by Karolinska Institutet University Library user on 17 July 2020 IBD are not characterized by a significant increase in mortality 12 , so the possible benefits of DTT need to be carefully weighed in terms of cost-effectiveness and safety. In our cohort, no opportunistic nor serious infections were recorded and no malignancies were diagnosed.…”

Section: Discussionsupporting

confidence: 60%

Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease

Privitera

Onali

Pugliese

et al. 2020

Journal of Crohn's and Colitis

Self Cite

View full text Add to dashboard Cite

Background and aims Dual Targeted Therapy (DTT) has been proposed as a novel therapeutic strategy for the management of complicated patients with Inflammatory Bowel Diseases (IBD). Our aim was to investigate the safety and effectiveness of this approach in a real-life setting. Methods We retrospectively extracted data from IBD patients receiving DTT in Italian IBD referral centres. Baseline characteristics, clinical activity of intestinal and extraintestinal disease and C-reactive proteins levels were recorded. All adverse events were reported. Clinical effectiveness, biochemical remission and safety of DTT were investigated. Results Sixteen patients were identified; indications for DTT were: “active IBD” or “active EIM” despite ongoing biological therapy. The most commonly used DTT were: vedolizumab + ustekinumab (3 patients) and vedolizumab + adalimumab (3 patients). Clinical response of intestinal or extraintestinal symptoms, according to the indication for DTT, was reported by all patients by the end of the induction. Four patients discontinued DTT during follow-up. Three patients experienced an adverse event; no serious adverse event was reported. Conclusions DTT seems to be an effective and safe treatment and may represent an appealing therapeutic strategy for the management of complicated IBD patients.

show abstract

Section: Discussionsupporting

confidence: 60%